Chongqing Xingchuang Pharmaceutical Co., Ltd.

Chongqing Xingchuang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Zhien Pharmaceutical Co., Ltd. It is a B2B commercial company centered on the wholesale and logistics distribution of Western medicine, traditional Chinese medicine, and medical devices. At the same time, through the Zhien Pharmacy chain, it has formed a retail system serving C-end users based on retail chains and e-commerce. Based on the Chongqing Kuanren Pharmacy chain, it realizes the MAH business model based on "medical application scenarios + products," and builds a new pharmaceutical retail model driven by data.
The main target markets are:
Domestic non-hospital market, including but not limited to chain pharmacies, independent pharmacies, clinics, etc.
Overseas markets, including intermediates, APIs, and formulation markets, etc.
The target customers are: MAH companies, CSO companies, channel companies, and C-end users.
Basic business logic: through data management of logistics, information flow, and capital flow, guide professional resources such as real-world study (RWS) and fintech, gather and serve CSOs, promote their support for shared decision-making between doctors and patients and rational drug use, and maximize patient benefits.
Real-world study is a non-randomized, open-label study that does not use placebos and is based on real clinical situations. Therefore, its results have high external validity, and the conclusions of the study can be directly applied to clinical practice.